Skip to contentT
Tenax Therapeutics, Inc.
T
TENXTenax Therapeutics, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derivedno prior Q4 2024 on file Net Income-$15.54M-$15.54MderivedN/M vs Q4 2024 EPS, diluted—Not derived. Share counts vary by quarter.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
Operating Incomederived-$16,449,000N/M Operating Cash Flowderived-$13,415,000N/M ended Dec 31, 2025 · filed Mar 10, 2026 · 69 d after period end